Rocket Pharmaceuticals (RCKT) Competitors $11.56 +0.21 (+1.85%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RCKT vs. RARE, BHVN, APLS, IMVT, SRRK, RNA, OGN, PTCT, VRNA, and RYTMShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Scholar Rock (SRRK), Avidity Biosciences (RNA), Organon & Co. (OGN), PTC Therapeutics (PTCT), Verona Pharma (VRNA), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Rocket Pharmaceuticals vs. Ultragenyx Pharmaceutical Biohaven Apellis Pharmaceuticals Immunovant Scholar Rock Avidity Biosciences Organon & Co. PTC Therapeutics Verona Pharma Rhythm Pharmaceuticals Ultragenyx Pharmaceutical (NASDAQ:RARE) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Does the MarketBeat Community believe in RARE or RCKT? Ultragenyx Pharmaceutical received 440 more outperform votes than Rocket Pharmaceuticals when rated by MarketBeat users. Likewise, 77.43% of users gave Ultragenyx Pharmaceutical an outperform vote while only 73.17% of users gave Rocket Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUltragenyx PharmaceuticalOutperform Votes83077.43% Underperform Votes24222.57% Rocket PharmaceuticalsOutperform Votes39073.17% Underperform Votes14326.83% Which has stronger valuation & earnings, RARE or RCKT? Rocket Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$522.75M7.81-$606.64M-$6.47-6.83Rocket PharmaceuticalsN/AN/A-$245.60M-$2.75-4.20 Do institutionals and insiders believe in RARE or RCKT? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 5.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is RARE or RCKT more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -106.93%. Rocket Pharmaceuticals' return on equity of -62.62% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-106.93% -187.12% -37.55% Rocket Pharmaceuticals N/A -62.62%-54.17% Do analysts rate RARE or RCKT? Ultragenyx Pharmaceutical currently has a consensus price target of $88.46, suggesting a potential upside of 100.05%. Rocket Pharmaceuticals has a consensus price target of $48.80, suggesting a potential upside of 322.15%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Rocket Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has more risk and volatility, RARE or RCKT? Ultragenyx Pharmaceutical has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Does the media favor RARE or RCKT? In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 15 mentions for Rocket Pharmaceuticals and 13 mentions for Ultragenyx Pharmaceutical. Rocket Pharmaceuticals' average media sentiment score of 0.69 beat Ultragenyx Pharmaceutical's score of 0.58 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryRocket Pharmaceuticals beats Ultragenyx Pharmaceutical on 11 of the 17 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05B$6.57B$5.06B$9.08BDividend YieldN/A3.11%4.84%4.21%P/E Ratio-4.2010.55102.6717.15Price / SalesN/A195.041,121.74116.80Price / CashN/A57.1641.3037.88Price / Book2.125.104.744.78Net Income-$245.60M$151.51M$119.11M$225.60M7 Day Performance-3.83%-2.13%-1.86%-1.21%1 Month Performance-11.08%-3.13%11.37%3.09%1 Year Performance-59.55%11.54%30.22%16.48% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.8035 of 5 stars$11.56+1.9%$48.80+322.1%-58.6%$1.05BN/A-4.20240Analyst ForecastHigh Trading VolumeRAREUltragenyx Pharmaceutical4.4437 of 5 stars$46.29+1.1%$87.46+88.9%-2.6%$4.27B$434.25M-7.081,276Analyst ForecastNews CoverageBHVNBiohaven3.7123 of 5 stars$40.92+6.4%$63.00+54.0%-4.4%$4.14B$462.51M-4.11239Analyst ForecastAPLSApellis Pharmaceuticals4.5591 of 5 stars$33.25+0.2%$49.94+50.2%-39.6%$4.14B$396.59M-16.35702Analyst DowngradePositive NewsIMVTImmunovant1.4648 of 5 stars$27.56+4.9%$47.89+73.8%-28.5%$4.05BN/A-11.84120Analyst ForecastNews CoverageSRRKScholar Rock3.879 of 5 stars$43.01+2.5%$40.43-6.0%+152.3%$4.03B$33.19M-18.35140Positive NewsRNAAvidity Biosciences2.1843 of 5 stars$33.62+3.5%$63.60+89.2%+278.8%$4.01B$10.12M-11.28190Analyst ForecastInsider TradeAnalyst RevisionNews CoverageOGNOrganon & Co.4.794 of 5 stars$14.74-3.7%$21.33+44.7%+10.9%$3.80B$6.26B2.9110,000PTCTPTC Therapeutics3.6544 of 5 stars$47.75+3.0%$54.08+13.3%+71.0%$3.68B$937.82M-7.811,410Analyst DowngradePositive NewsVRNAVerona Pharma0.7085 of 5 stars$43.28+4.5%$43.83+1.3%+153.4%$3.52B$460,000.00-21.5730Gap DownRYTMRhythm Pharmaceuticals4.1088 of 5 stars$56.06+1.5%$63.70+13.6%+25.1%$3.45B$77.43M-12.76140Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies RARE Competitors BHVN Competitors APLS Competitors IMVT Competitors SRRK Competitors RNA Competitors OGN Competitors PTCT Competitors VRNA Competitors RYTM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RCKT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCKT Stock Alerts